Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T08:23:15.307Z Has data issue: false hasContentIssue false
  • English
  • Français

Monitoring of extrapyramidal side effects in patients on antipsychotic treatment: a completed audit cycle

Published online by Cambridge University Press:  03 August 2015

MI Butler  and
J Chandrakanth
MI Butler*
Affiliation:
Community Mental Health Centre, South Tipperary Mental Health Services, Clonmel, Co Tipperary
J Chandrakanth
Affiliation:
Community Mental Health Centre, South Tipperary Mental Health Services, Clonmel, Co Tipperary
*
*Address for correspondence: M. Butler, Department of Liaison Psychiatry, Beaumont Hospital, Dublin. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Movement disorders are a common problem in those receiving antipsychotic medication. Clinical guidelines recommend that these side-effects are monitored regularly throughout treatment. However, due to a lack of training, clinician confidence levels in assessment are often low and regular monitoring may be neglected.

Aims

To audit current practice in our services regarding monitoring of extrapyramidal side effects (EPSE) and improve monitoring through education of clinicians.

Method

The clinical records of patients receiving antipsychotic treatment, seen in the outpatient clinic over a 2-week period, were reviewed. Data were collected on whether or not EPSE had been assessed. A re-audit was undertaken following a teaching session.

Results

Documentation regarding EPSE was present in only 14% of patient records. Following a teaching session, the overall level of documentation of EPSE rose to 42%, with rates of assessment dramatically improving in non-consultant hospital doctors.

Conclusion

In our practice, clinicians are generally poor to assess and record EPSE. However, rates of assessment improved significantly following a teaching session, especially in NCHDs.

Keywords

Antipsychoticauditextrapyramidal side effects
Type
Short Report
Information
Irish Journal of Psychological Medicine , Volume 33 , Issue 3 , September 2016 , pp. 165 - 169
Copyright
© College of Psychiatrists of Ireland 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (2004). American Psychiatric Association: practice guideline for the treatment of patients with schizophrenia second edition. American Journal of Psychiatry 154 (Suppl.): 1–63.Google Scholar
Barnes, TRE, McPhillips, MA (1996). Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment. CNS Drugs 6, 315–330.CrossRefGoogle Scholar
Browne, S, Roe, M, Lane, A, Gervin, M, Morris, M, Kinsella, A, Larkin, C, Callaghan, EO (1996). Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica 94, 118–124.Google Scholar
Cortese, L, Jog, M, McAuley, T, Kotteda, V, Costa, G (2004). Assessing and monitoring antipsychotic-induced movement disorders in hospitalized patients: a cautionary study. Canadian Journal of Psychiatry 49, 31–36.Google Scholar
Gao, K, Kemp, DE, Ganocy, SJ, Gajwani, P, Xia, G, Calabrese, JR (2008). Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology 28, 203–209.Google Scholar
Gervin, M, Barnes, TRE. (2000). Assessment of drug-related movement disorders in schizophrenia. Advances in Psychiatric Treatment 6, 332–341.Google Scholar
Hansen, TE, Brown, WL, Weigel, RM, Casey, DE (1992). Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. General Hospital Psychiatry 14, 340–344.Google Scholar
Hirose, S (2003). The causes of underdiagnosing akathisia. Schizophrenia Bulletin 29, 547–558.Google Scholar
Kuruvilla, KA, Sedano-Ruiz, A, Ley, A. (2006). Drug-related movement disorders: training experiences of psychiatrists. The Psychiatrist 30, 300–303.Google Scholar
Miller, CH, Mohr, F, Umbricht, D, Woerner, M, Fleischhacker, WW, Lieberman, JA. (1998). The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. The Journal of Clinical Psychiatry 59, 69–75.Google Scholar
NICE (2009). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE clinical guideline No 82. London. National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/cg82 f. Accessed 14 January 2013.Google Scholar
Pappa, S, Dazzan, P. (2009). Spontaneous movement disorders in antipsychotic-naïve patients with first-episode psychosis; a systematic review. Psychological Medicine 39, 1065–1076.Google Scholar
Tenback, DE, Vanharten, PN, Slooff, CJ, Van Os, J (2010). Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. Journal of Psychopharmacology 24, 1031–1035.Google Scholar
Weiden, PJ, Mann, JJ, Mattson, M, Frances, A (1987). Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. American Journal of Psychiatry 144, 1148–1153.Google Scholar